Product information and disease descriptionProduct descriptionProduct information
Dosage forms and strengths
1 evidence topic · 1 source
Chinese marketed presentation
Material safety data sheet
No evidence found.
Ivonescimab
EGFR-mutated non-small-cell lung cancer
- Manufacturer
- Summit Therapeutics
- Regulatory submission
- BLA submitted in the fourth quarter of 2025
- Launch
- Not announced
- Last updated